New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn
Posted: 2025-01-12 17:00:00
Globe NewsWire News Distribution Service
Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
- Details
- Written by Globe NewsWire Press Releases
- Category: Globe NewsWire News Distribution Service
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn
Posted: 2025-01-12 17:00:00
Listen to this article. Speaker link opens in a new window.
Related News Stories From The Web And More
Related Bing News Search Results
Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results - Newscast
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Wed, 05 Feb 2025 03:38:00 GMT Exagen Inc. (XGN) shares soared 29.4% in the last trading session to close at $5.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...Exagen Inc. to Participate in Upcoming Investor Conferences
Tue, 04 Feb 2025 13:26:00 GMT CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming ...Exagen Inc. Gains Approval for Advanced Lupus and Rheumatoid Arthritis Diagnostic Tests
Mon, 13 Jan 2025 16:00:00 GMT Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker assays designed to improve the detection of systemic lupus erythematosus ...Exagen Gets Conditional Approval For New Lupus And RA Biomarker Assays In New York
Sun, 12 Jan 2025 05:04:00 GMT (RTTNews) - Exagen Inc. (XGN), a provider of autoimmune testing, said that it has received conditional approval from the New York State Department of Health for its new systemic lupus ...Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis ...
Sat, 11 Jan 2025 15:59:00 GMT Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn ...
